Clinical trial · Interventional
Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile
Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Open label, single dose and phase I study. The primary objective: To determine the maximum tolerated dose in Single dose The secondary objective: to evaluate the toxicity in administration to determine desirable dosing amount for phase II to evaluate tumor response in progressive solid cancer patients to evaluate pharmacokinetic/ pharmacodynamic profile.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumour | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CG200745 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Single Arm for CG200745
- description
- any progrossive solid cancer
- interventionNames
- Drug: CG200745
Primary outcomes (1)
- measure
- To determine the maximum tolerated dose in Single dose
- timeFrame
- On 22 days after administration
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 69 Years
Show eligibility criteria text
Inclusion Criteria: * from 20 years old to 69 years old * diagnosed with progressive solid cancer * In spite of standard chemotherapies, the efficacy of the treatment or life extension cannot be expected. * Evaluated 0-1 of ECOG * Expected life duration is within 3 months Exclusion Criteria: * Major surgery except tumor-removal surgery received within 2 weeks of screening. * history of CNS metasis * hyper-sensitivy of study drug * pregancy or lactating * administered other HDAC inhibitor within 4 weeks of screening
References
Publications (0)
Data not yet available